An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company, will participate virtually in the Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 2:40 p.m. ET. The company focuses on innovative therapies for treating glaucoma and other eye disorders, including corneal and retinal diseases. The event will be accessible via webcast on Glaukos' Investor Relations website. Glaukos has pioneered Micro-Invasive Glaucoma Surgery (MIGS) and continues to develop its portfolio of surgical and pharmaceutical therapies.
Positive
Company's participation in a prominent healthcare conference could enhance investor visibility.
Focus on innovative therapies positions Glaukos favorably in the ophthalmic medical sector.
Negative
None.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 2:40 p.m. ET.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent injectW device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
